# Association study between clinical response to rizatriptan and some candidate genes

## Metadata
**Authors:** Carlo Asuni, Allesandra Cherchi, Donatella Congiu, Maria P Piccardi, Maria Del Zompo, Maria E Stochino
**Journal:** The Journal of Headache and Pain
**Date:** 2007 Jun 11
**DOI:** [10.1007/s10194-007-0388-5](https://doi.org/10.1007/s10194-007-0388-5)
**PMID:** 17563839
**PMCID:** PMC3476140
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476140/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC3476140/pdf/10194_2007_Article_388.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC3476140/pdf/10194_2007_Article_388.pdf)

## Abstract

The aim of this study was to test genetic differences in the clinical response to rizatriptan in patients affected by migraine without aura. These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT1 receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD2 (gene encoding the D2 receptor), both involved in the pathogenesis of migraine. Fifty unrelated patients affected by migraine without aura (IHS) were included. Patients were divided into two groups (responders and non-responders) according to clinical response. Thirty-one out of fifty patients responded to rizatriptan. A significant difference among the two groups was observed in both allele (p=0.02) and genotype distribution (p=0.03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan.

Keywords: Migraine, Triptans, Pharmacogenetics, Dopamine, DRD2

## Full Text

The Full Text of this article is available as a [PDF](/articles/instance/3476140/pdf/10194_2007_Article_388.pdf) (58.9 KB).

## References

1. Visser W.H., Burggraaf J., Muller L.M., et al. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther. 1996;60:452–460. doi: 10.1016/S0009-9236(96)90202-7.  [DOI](https://doi.org/10.1016/S0009-9236(96)90202-7) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8873693/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Pharmacokinetic%20and%20pharmacodynamic%20profiles%20of%20sumatriptan%20in%20migraine%20patients%20with%20headache%20recurrence%20or%20no%20response&author=W.H.%20Visser&author=J.%20Burggraaf&author=L.M.%20Muller&volume=60&publication_year=1996&pages=452-460&pmid=8873693&doi=10.1016/S0009-9236(96)90202-7&)

2. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675. doi: 10.1016/S0140-6736(01)06711-3.  [DOI](https://doi.org/10.1016/S0140-6736(01)06711-3) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11728541/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Oral%20triptans%20(serotonin%205-HT1B/1D%20agonists)%20in%20acute%20migraine%20treatment:%20a%20meta-analysis%20of%2053%20trials&author=M.D.%20Ferrari&author=K.I.%20Roon&author=R.B.%20Lipton&author=P.J.%20Goadsby&volume=358&publication_year=2001&pages=1668-1675&pmid=11728541&doi=10.1016/S0140-6736(01)06711-3&)

3. Waeber C., Moskowitz M.A. Therapeutic implications of central and peripheral neurologic mechanisms in migraine. Neurology. 2003;61([Suppl4]):S9–S20. doi: 10.1212/wnl.61.8_suppl_4.s9.  [DOI](https://doi.org/10.1212/wnl.61.8_suppl_4.s9) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/14581653/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Therapeutic%20implications%20of%20central%20and%20peripheral%20neurologic%20mechanisms%20in%20migraine&author=C.%20Waeber&author=M.A.%20Moskowitz&volume=61&issue=%5BSuppl4%5D&publication_year=2003&pages=S9-S20&pmid=14581653&doi=10.1212/wnl.61.8_suppl_4.s9&)

4. Maassen VanDenBrink A., Broek R.W.M., Vries R., et al. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology. 2000;55:1524–1530. doi: 10.1212/wnl.55.10.1524.  [DOI](https://doi.org/10.1212/wnl.55.10.1524) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11094108/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Craniovascular%20selectivity%20of%20eletriptan%20and%20sumatriptan%20in%20human%20isolated%20blood%20vessels&author=A.%20Maassen%20VanDenBrink&author=R.W.M.%20Broek&author=R.%20Vries&volume=55&publication_year=2000&pages=1524-1530&pmid=11094108&doi=10.1212/wnl.55.10.1524&)

5. Peroutka S.J. Dopamine and migraine. Neurology. 1997;49:650–656. doi: 10.1212/wnl.49.3.650.  [DOI](https://doi.org/10.1212/wnl.49.3.650) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9305317/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Dopamine%20and%20migraine&author=S.J.%20Peroutka&volume=49&publication_year=1997&pages=650-656&pmid=9305317&doi=10.1212/wnl.49.3.650&)

6. Peroutka S.J., Wilholt T., Jones K. Clinical susceptibility in migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997;49:201–206. doi: 10.1212/wnl.49.1.201.  [DOI](https://doi.org/10.1212/wnl.49.1.201) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9222191/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Clinical%20susceptibility%20in%20migraine%20with%20aura%20is%20modified%20by%20dopamine%20D2%20receptor%20(DRD2)%20NcoI%20alleles&author=S.J.%20Peroutka&author=T.%20Wilholt&author=K.%20Jones&volume=49&publication_year=1997&pages=201-206&pmid=9222191&doi=10.1212/wnl.49.1.201&)

7. Zompo M., Cherchi A., Palmas M.A., et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998;51:781–786. doi: 10.1212/wnl.51.3.781.  [DOI](https://doi.org/10.1212/wnl.51.3.781) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9748026/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Neurology&title=Association%20between%20dopamine%20receptor%20genes%20and%20migraine%20without%20aura%20in%20a%20Sardinian%20sample&author=M.%20Zompo&author=A.%20Cherchi&author=M.A.%20Palmas&volume=51&publication_year=1998&pages=781-786&pmid=9748026&doi=10.1212/wnl.51.3.781&)

8. Mathew N.T., Kailasam J., Gentry P., Chernyshev O. Treatment on nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trials. Headache. 2000;40:464–465. doi: 10.1046/j.1526-4610.2000.00069.x.  [DOI](https://doi.org/10.1046/j.1526-4610.2000.00069.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/10849042/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Headache&title=Treatment%20on%20nonresponders%20to%20oral%20sumatriptan%20with%20zolmitriptan%20and%20rizatriptan:%20a%20comparative%20open%20trials&author=N.T.%20Mathew&author=J.%20Kailasam&author=P.%20Gentry&author=O.%20Chernyshev&volume=40&publication_year=2000&pages=464-465&pmid=10849042&doi=10.1046/j.1526-4610.2000.00069.x&)

9. Sarkar G., Kapelner S., Grandy D.K., et al. Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics. 1991;11:8–14. doi: 10.1016/0888-7543(91)90096-W.  [DOI](https://doi.org/10.1016/0888-7543(91)90096-W) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/1837284/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Genomics&title=Direct%20sequencing%20of%20the%20dopamine%20D2%20receptor%20(DRD2)%20in%20schizophrenics%20reveals%20three%20polymorphisms%20but%20no%20structural%20change%20in%20the%20receptor&author=G.%20Sarkar&author=S.%20Kapelner&author=D.K.%20Grandy&volume=11&publication_year=1991&pages=8-14&pmid=1837284&doi=10.1016/0888-7543(91)90096-W&)

10. Arinami T., Gao M., Hamaguchi H., Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associate with schizophrenia. Hum Mol Genet. 1997;6:577–582. doi: 10.1093/hmg/6.4.577.  [DOI](https://doi.org/10.1093/hmg/6.4.577) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9097961/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Hum%20Mol%20Genet&title=A%20functional%20polymorphism%20in%20the%20promoter%20region%20of%20the%20dopamine%20D2%20receptor%20gene%20is%20associate%20with%20schizophrenia&author=T.%20Arinami&author=M.%20Gao&author=H.%20Hamaguchi&author=M.%20Toru&volume=6&publication_year=1997&pages=577-582&pmid=9097961&doi=10.1093/hmg/6.4.577&)

11. Lesch K.P., Bengel D., Heils A., et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527–1531. doi: 10.1126/science.274.5292.1527.  [DOI](https://doi.org/10.1126/science.274.5292.1527) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8929413/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Science&title=Association%20of%20anxiety-related%20traits%20with%20a%20polymorphism%20in%20the%20serotonin%20transporter%20gene%20regulatory%20region&author=K.P.%20Lesch&author=D.%20Bengel&author=A.%20Heils&volume=274&publication_year=1996&pages=1527-1531&pmid=8929413&doi=10.1126/science.274.5292.1527&)

12. Lappalainen J., Dean M., Charbonneau L., et al. Mapping of serotonin 5-HT1D, autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Genet. 1995;60:157–161. doi: 10.1002/ajmg.1320600214.  [DOI](https://doi.org/10.1002/ajmg.1320600214) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/7485252/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Med%20Genet&title=Mapping%20of%20serotonin%205-HT1D,%20autoreceptor%20gene%20on%20chromosome%206%20and%20direct%20analysis%20for%20sequence%20variants&author=J.%20Lappalainen&author=M.%20Dean&author=L.%20Charbonneau&volume=60&publication_year=1995&pages=157-161&pmid=7485252&doi=10.1002/ajmg.1320600214&)

13. Hotamisligil G.S., Breakefield X.O. Human monoamine oxidase A gene determines levels of enzyme activity. Am J Hum Genet. 1991;49:383–392.  [PMC free article](/articles/PMC1683299/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/1678250/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Hum%20Genet&title=Human%20monoamine%20oxidase%20A%20gene%20determines%20levels%20of%20enzyme%20activity&author=G.S.%20Hotamisligil&author=X.O.%20Breakefield&volume=49&publication_year=1991&pages=383-392&pmid=1678250&)

14. Ott J. Analysis of human genetic linkage. Baltimore: Johns Hopkins University Press; 1999.  [Google Scholar](https://scholar.google.com/scholar_lookup?title=Analysis%20of%20human%20genetic%20linkage&author=J.%20Ott&publication_year=1999&)

15. Sham P.C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet. 1995;59:97–105. doi: 10.1111/j.1469-1809.1995.tb01608.x.  [DOI](https://doi.org/10.1111/j.1469-1809.1995.tb01608.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/7762987/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Ann%20Hum%20Genet&title=Monte%20Carlo%20tests%20for%20associations%20between%20disease%20and%20alleles%20at%20highly%20polymorphic%20loci&author=P.C.%20Sham&author=D.%20Curtis&volume=59&publication_year=1995&pages=97-105&pmid=7762987&doi=10.1111/j.1469-1809.1995.tb01608.x&)

16. Maassen VanDenBrink A., Vergouwe M.N., Ophoff R.A., et al. 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache. 1998;38:288–291. doi: 10.1046/j.1526-4610.1998.3804288.x.  [DOI](https://doi.org/10.1046/j.1526-4610.1998.3804288.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9595868/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Headache&title=5-HT1B%20receptor%20polymorphism%20and%20clinical%20response%20to%20sumatriptan&author=A.%20Maassen%20VanDenBrink&author=M.N.%20Vergouwe&author=R.A.%20Ophoff&volume=38&publication_year=1998&pages=288-291&pmid=9595868&doi=10.1046/j.1526-4610.1998.3804288.x&)

17. Maassen VanDenBrink A., Vergouwe M.N., Ophoff R.A., et al. Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet. 1998;77:415–420. doi: 10.1002/(SICI)1096-8628(19980605)77:5<415::AID-AJMG12>3.0.CO;2-L.  [DOI](https://doi.org/10.1002/(SICI)1096-8628(19980605)77:5&#x0003c;415::AID-AJMG12&#x0003e;3.0.CO;2-L) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9632173/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Am%20J%20Med%20Genet&title=Chromosomal%20localization%20of%20the%205-HT1F%20receptor%20gene:%20no%20evidence%20for%20involvement%20in%20response%20to%20sumatriptan%20in%20migraine%20patients&author=A.%20Maassen%20VanDenBrink&author=M.N.%20Vergouwe&author=R.A.%20Ophoff&volume=77&publication_year=1998&pages=415-420&pmid=9632173&doi=10.1002/(SICI)1096-8628(19980605)77:5&#x0003c;415::AID-AJMG12&#x0003e;3.0.CO;2-L&)

18. Ophoff R.A., Maagdenberg A., Roon K.I., et al. The impact of pharmacogenetics for migraine. Eur J Pharmacol. 2001;413:1–10. doi: 10.1016/S0014-2999(00)00949-3.  [DOI](https://doi.org/10.1016/S0014-2999(00)00949-3) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11173058/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Pharmacol&title=The%20impact%20of%20pharmacogenetics%20for%20migraine&author=R.A.%20Ophoff&author=A.%20Maagdenberg&author=K.I.%20Roon&volume=413&publication_year=2001&pages=1-10&pmid=11173058&doi=10.1016/S0014-2999(00)00949-3&)

19. Iadecola C. Neurogenic control of the cerebral circulation: is dopamine minding the store? Nature Neurosci. 1998;1:263–265. doi: 10.1038/1074.  [DOI](https://doi.org/10.1038/1074) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/10195155/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature%20Neurosci&title=Neurogenic%20control%20of%20the%20cerebral%20circulation:%20is%20dopamine%20minding%20the%20store?&author=C.%20Iadecola&volume=1&publication_year=1998&pages=263-265&pmid=10195155&doi=10.1038/1074&)

20. Basu S., Nagy J.A., Pal S., et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Med. 2001;7:569–574. doi: 10.1038/87895.  [DOI](https://doi.org/10.1038/87895) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11329058/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nature%20Med&title=The%20neurotransmitter%20dopamine%20inhibits%20angiogenesis%20induced%20by%20vascular%20permeability%20factor/vascular%20endothelial%20growth%20factor&author=S.%20Basu&author=J.A.%20Nagy&author=S.%20Pal&volume=7&publication_year=2001&pages=569-574&pmid=11329058&doi=10.1038/87895&)
